{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:52:52Z","timestamp":1781927572532,"version":"3.54.5"},"reference-count":20,"publisher":"Japan Neurosurgical Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.2176\/jns-nmc.2025-0293","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:10:00Z","timestamp":1775167800000},"page":"363-370","source":"Crossref","is-referenced-by-count":0,"title":["First-year Experience with Brivaracetam in Japan: Real-world Data from Juntendo Epilepsy Center"],"prefix":"10.2176","volume":"66","author":[{"given":"Yasushi","family":"IIMURA","sequence":"first","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"NOMURA","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"MITSUHASHI","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroharu","family":"SUZUKI","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"UEDA","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"NISHIOKA","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"TSUNEMI","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurology, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"UENO","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurology, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"SUGANO","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"},{"name":"Sugano Neurosurgery Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"KONDO","sequence":"additional","affiliation":[{"name":"Epilepsy Center, Juntendo University Hospital"},{"name":"Department of Neurosurgery, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","unstructured":"1) Epilepsy clinical guidelines. The Guideline Committee for the Treatment of Epilepsy, Japanese Society of Neurology (ed). 2018. Japanese."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78 (20):1548-54. doi: 10.1212\/WNL.0b013e3182563b19","DOI":"10.1212\/WNL.0b013e3182563b19"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75 (3):279-86. doi: 10.1001\/jamaneurol.2017.3949","DOI":"10.1001\/jamaneurol.2017.3949"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of Brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664 (1-3):36-44. doi: 10.1016\/j.ejphar.2011.04.064","DOI":"10.1016\/j.ejphar.2011.04.064"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Serrano-Castro PJ, Caballero-Mart\u00ednez F, Campos-Lucas FJ, et al. Effectiveness and safety of early add-on therapy with Brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV-add study. Epilepsia Open. 2025;10 (5):1334-44. doi: 10.1002\/epi4.70073","DOI":"10.1002\/epi4.70073"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Steinhoff BJ, Christensen J, Doherty CP, et al. Effectiveness during 12-month adjunctive Brivaracetam treatment in patients with focal-onset seizures in a real-life setting: a prospective, observational study in Europe. Neurol Ther. 2025;14 (2):627-42. doi: 10.1007\/s40120-024-00697-4","DOI":"10.1007\/s40120-024-00697-4"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Meador KJ, Laloyaux C, Elmoufti S, et al. Time course of drug-related treatment-emergent adverse side effects of Brivaracetam. Epilepsy Behav. 2020;111:107212. doi: 10.1016\/j.yebeh.2020.107212","DOI":"10.1016\/j.yebeh.2020.107212"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Szaflarski JP, Besson H, D'Souza W, et al. Effectiveness and tolerability of Brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol. 2024;271 (6):3169-85. doi: 10.1007\/s00415-024-12253-z","DOI":"10.1007\/s00415-024-12253-z"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Naddell S, Manuel M, Cavill R, et al. BRIVEST: a 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam. Epilepsy Behav. 2023;138:108985. doi: 10.1016\/j.yebeh.2022.108985","DOI":"10.1016\/j.yebeh.2022.108985"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Villanueva V, Villar EG, Fernandez-Cabrera A, et al. BRIVA-ONE study: 12-month outcomes of Brivaracetam monotherapy in clinical practice. Epilepsia Open. 2024;9 (6):2429-42. doi: 10.1002\/epi4.13078","DOI":"10.1002\/epi4.13078"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Asadi-Pooya AA, Sperling MR, Chung S, et al. Efficacy and tolerability of adjunctive Brivaracetam in patients with prior antiepileptic drug exposure: a post-hoc study. Epilepsy Res. 2017;131:70-5. doi: 10.1016\/j.eplepsyres.2017.02.007","DOI":"10.1016\/j.eplepsyres.2017.02.007"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Strzelczyk A, Zaveta C, von Podewils F, et al. Long-term efficacy, tolerability, and retention of Brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up. Epilepsia. 2021;62 (12):2994-3004. doi: 10.1111\/epi.17087","DOI":"10.1111\/epi.17087"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Hirsch M, Hintz M, Specht A, et al. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98-103. doi: 10.1016\/j.seizure.2018.07.017","DOI":"10.1016\/j.seizure.2018.07.017"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14) Snoeren A, Majoie MHJM, Fasen KCFM, et al. Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: a retrospective outcome analysis. Seizure. 2022;96:102-7. doi: 10.1016\/j.seizure.2022.02.007","DOI":"10.1016\/j.seizure.2022.02.007"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Inoue Y, Tiamkao S, Zhou D, et al. Efficacy, safety, and tolerability of adjunctive Brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia Open. 2024;9 (3):1007-20. doi: 10.1002\/epi4.12929","DOI":"10.1002\/epi4.12929"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Fujimoto A, Qin B, Bourikas D, et al. Safety, tolerability, and efficacy of adjunctive Brivaracetam in Japanese and Chinese patients with focal-onset seizures: interim analysis of a phase 3 open-label extension trial. Adv Ther. 2025;42 (9):4335-49. doi: 10.1007\/s12325-025-03253-0","DOI":"10.1007\/s12325-025-03253-0"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019;15:2587-600. doi: 10.2147\/NDT.S143548","DOI":"10.2147\/NDT.S143548"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Klitgaard H, Matagne A, Nicolas JM, et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57 (4):538-48. doi: 10.1111\/epi.13340.","DOI":"10.1111\/epi.13340"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003;61 (9):1218-21. doi: 10.1212\/01.WNL.0000091865.46063.67","DOI":"10.1212\/01.WNL.0000091865.46063.67"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Lee JJ, Song HS, Hwang YH, et al. Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. J Clin Neurol. 2011;7 (3):128-36. doi: 10.3988\/jcn.2011.7.3.128","DOI":"10.3988\/jcn.2011.7.3.128"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/66\/6\/66_2025-0293\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:38:29Z","timestamp":1781926709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/66\/6\/66_2025-0293\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2025-0293","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"2025-0293"}}